

## CHAPTER

# 11

### 참고 문헌

1. ACOG Committee on Practices Bulletins-Gynecology. ACOG Practice Bulletin No. 51. Chronic pelvic pain. *Obstet Gynecol* 2006;103:589-605.
2. ACOG criteria set. Hysterectomy, abdominal or vaginal for chronic pelvic pain. Number 29, November 1997. Committee on Quality Assessment, American College of Obstetricians and Gynecologists. *Int J Gynaecol Obstet* 1998;60(3):316-7.
3. Ahangari A. Prevalence of chronic pelvic pain among women: an updated review. *Pain Physician* 2014;17:E141.
4. Akin M, Price W, Rodriguez G Jr, Erasala G, Hurley G, Smith RP. Continuous, low-level, topical heat wrap therapy as compared to acetaminophen for primary dysmenorrhea. *J Reprod Med* 2004;49:739.
5. Akin MD, Weingand KW, Hengehold DA, Goodale MB, Hinkle RT, Smith RP. Continuous low-level topical heat in the treatment of dysmenorrhea. *Obstet Gynecol* 2001;97:343.
6. Altunyurt S, Gol M, Sezer O, Demir N. Primary dysmenorrhea and uterine blood flow: a color Doppler study. *J Reprod Med* 2005;50:251.
7. Alvin PE, Litt IF. Current status of the etiology and management of dysmenorrhea in adolescence. *Pediatrics* 1982;70:516.
8. Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. *Am J Obstet Gynecol* 1982;144:655-60.
9. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. *Contraception* 2006;73:229.
10. Anderson FD, Hait H, Amulticenter, randomized study of an extended cycle oral contraceptive. *Contraception* 2003;68:89.
11. Athanasiou S, Bourne TH, Khalid A, Okokon EV, Crayford TJ, Hagstrom HG, et al. Effects of indomethacin on follicular structure, vascularity, and function over the periovulatory period in women. *Fertil Steril* 1996;65:556.
12. Barnard ND, Scialli AR, Hurlock D, Bertron P. Diet and sex-hormone binding globulin, dysmenorrhea, and premenstrual symptoms. *Obstet Gynecol* 2000;95:245.
13. Beard RW, Reginald PW, Wadsworth J. Clinical features of women with chronic lower abdominal pain and pelvic congestion. *Br J Obstet Gynaecol* 1988;95:153.
14. Budoff PW. Use of mefenamic acid in the treatment of primary dysmenorrhea. *JAMA* 1979;241:2713.
15. Chan WY, Dawood MY, Fuchs F. Prostaglandins in primary dysmenorrhea. Comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. *Am J Med* 1981;70:535.
16. Davis AR, Westhoff C, O'Connell K, Gallagher N. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. *Obstet Gynecol* 2005;106:97.
17. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. *Obstet Gynecol* 2006;108:428.
18. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. *MMWR Recomm Rep* 2016;65:1.
19. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. *Cochrane Database Syst Rev* 2005;(3):CD004695.
20. Fall M, Baranowski AP, Elneil S, et al. EAU guidelines on chronic pelvic pain. *Eur Urol* 2010;57:35.
21. Fenton BW, Palmieri P, Diantonio G, Vongruenigen V. Application of Patient-Reported Outcomes Measurement Information System to chronic pelvic pain. *J Minim Invasive Gynecol* 2011;18:189.
22. French L. Dysmenorrhea. *Am Fam Physician* 2005;71:285.
23. Golomb LM, Solidum AA, Warren MP. Primary dysmenor-

- rhea and physical activity. *Med Sci Sports Exerc* 1998;30:906.
24. Gyang A, Hartman M, Lamvu G. Musculoskeletal causes of chronic pelvic pain: what a gynecologist should know. *Obstet Gynecol* 2013;121:645.
25. Harel Z, Biro FM, Kollar LM. Depo-Provera in adolescents: effects of early second injection or prior oral contraception. *J Adolesc Health* 1995;16:379.
26. Heikinheimo O, Gemzell-Danielsson K. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS). *Acta Obstet Gynecol Scand* 2012;91(1):3.
27. Hellman KM, Patanwala IY, Pozolo KE, Tu FF. Multimodal nociceptive mechanisms underlying chronic pelvic pain. *Am J Obstet Gynecol* 2015;213:827.e1.
28. Henzl MR, Buttram V, Segre EJ, Bessler S. The treatment of dysmenorrhea with naproxen sodium: a report on two independent double-blind trials. *Am J Obstet Gynecol* 1977;127:818.
29. Hickey M, Ballard K, Farquhar C. Endometriosis. *BMJ* 2014;348:g1752.
30. Howard FM. Chronic pelvic pain. *Obstet Gynecol* 2003;101:594.
31. Jarrell J, Arendt-Nielsen L. Evolutionary considerations in the development of chronic pelvic pain. *Am J Obstet Gynecol* 2016;215:201.e1.
32. Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. *Pediatrics* 1981;68:661-4.
33. Larkin RM, Van Orden DE, Poulson AM, Scott JR. Dysmenorrhea: treatment with an antiprostaglandin. *Obstet Gynecol* 1979;54:456.
34. Latthe P, Mignini L, Gray R, Hills R, Khan K. Factors predisposing women to chronic pelvic pain: systematic review. *Br Med J* 2006;332:749.
35. Lee JC, Yu BK, Byeon JH, Lee KH, Min JH, Park SH. A study on the menstruation of Korean adolescent girls in Seoul. *Korean J Pediatr* 2011;54:201-6.
36. Lindh I, Milsom I. The influence of intrauterine contraception on the prevalence and severity of dysmenorrhea: a longitudinal population study. *Hum Reprod* 2013;28(7):1953.
37. Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. *Pelvic Pain Study Group*. *Obstet Gynecol* 1999;93:51.
38. Metheny WP, Smith RP. The relationship among exercise, stress, and primary dysmenorrhea. *J Behav Med* 1989;12:569.
39. Nickel JC, Tripp DA, International Interstitial Cystitis Study Group. Clinical and psychological parameters associated with pain pattern phenotypes in women with interstitial cystitis/bladder pain syndrome. *J Urol* 2015;193:138.
40. Norman RJ, Wu R. The potential danger of COX-2 inhibitors. *Fertil Steril* 2004;81:493.
41. Owen PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. *Am J Obstet Gynecol* 1984;148:96.
42. Passavanti MB, Pota V, Sansone P, Aurilio C, Nardis LD, Pace MC. Chronic Pelvic Pain: Assessment, Evaluation, and Objectivation. *Pain Res Treat* 2017;2017:9472925.
43. Possover M, Schneider T, Henle KP. Laparoscopic therapy for endometriosis and vascular entrapment of sacral plexus. *Fertil Steril* 2011;95:756.
44. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. *Fertil Steril* 2014;101:927.
45. Prior JC, Vigna Y, Alojada N. Conditioning exercise decreases premenstrual symptoms. A prospective controlled three month trial. *Eur J Appl Physiol Occup Physiol* 1986;55:349-55.
46. Proctor ML, Murphy PA. Herbal and dietary therapies for primary and secondary dysmenorrhea. *Cochrane Database Syst Rev* 2001;(3):CD002124.
47. Richter HE, Holley RL, Chandraiah S, Varner RE. Laparoscopic and psychologic evaluation of women with chronic pelvic pain. *Int J Psychiatry Med* 1998;28:243.
48. Roumen FJ. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. *Contraception* 2007;75:420.
49. Smith RP. Cyclic pelvic pain and dysmenorrhea. *Obstet Gynecol Clin North Am* 1993;20:753.
50. Speer LM, Mushkbar S, Erbele T. Chronic Pelvic Pain in Women. *Am Fam Physician* 2016; 93:380.
51. Stovall TG, Ling FW, Crawford DA. Hysterectomy for chronic pelvic pain of presumed uterine etiology. *Obstet Gynecol* 1990;75:676.
52. The 2015 EAU guidelines on chronic pelvic pain. <http://www.uroweb.org/guidelines/online-guidelines/> (Accessed on November 22, 2015).
53. Tirlapur SA, Daniels JP, Khan KS, MEDAL trial collaboration. Chronic pelvic pain: how does noninvasive imaging compare with diagnostic laparoscopy? *Curr Opin Obstet Gynecol* 2015;27:445.
54. Tu FF, Beaumont JL. Outpatient laparoscopy for abdominal and pelvic pain in the United States 1994 through 1996. *Am J Obstet Gynecol* 2006;194:699.
55. Tu FF, Hahn D, Steege JF. Pelvic congestion syndrome-associated pelvic pain: a systematic review of diagnosis and management. *Obstet Gynecol Surv* 2010;65:332.

56. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)—a systematic enquiry and overview. *Eur J Obstet Gynecol Reprod Biol* 2006;125:9.
57. Yucel N, Baskent E, Karamustafaoglu Balci B, Goynumer G. The levonorgestrel-releasing intrauterine system is associated with a reduction in dysmenorrhoea and dyspareunia, a decrease in CA 125 levels, and an increase in quality of life in women with suspected endometriosis. *Aust N Z J Obstet Gynaecol* 2018;58(5):560.
58. Zhu X, Proctor M, Bensoussan A, Smith CA, Wu E. Chinese herbal medicine for primary dysmenorrhea. *Cochrane Database Syst Rev* 2007;(4):CD005288.
59. Ziaei S, Faghihzadeh S, Sohrabvand F, Lamyian M, Emamgohly T. A randomised placebo-controlled trial to determine the effect of vitamin E in treatment of primary dysmenorrhea. *Br J Obstet Gynaecol* 2001;108:1181.
60. Ziaei S, Zakeri M, Kazemnejad A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhea. *Br J Obstet Gynaecol* 2005;112:466.